Trial Coordinator
CurrentEnest Freedom, Studio Clinico Novartis CAMN107I2201 “A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line nilotinib treatment Authors”